Search & Evaluation Early TA Lead, Director (CVR)

Serve as the senior Early S&E leader within the TALT, influencing therapeutic strategy and ensuring external innovation priorities are integrated into portfolio planning.​

Lead proactive sourcing and scouting efforts for preclinical and Phase 1 assets, building a robust pipeline of opportunities aligned with TA strategy. ​

Co-lead internal meetings (with Late Search Lead) focused on evaluating and prioritizing New Product Opportunities (NPOs) within each CSL’s therapeutic areas. NPO meetings are strategic checkpoints where cross-functional teams review potential assets identified by Search and decide whether to advance them for further due diligence and deal negotiations​

Develop and execute early partnering strategies, including onboarding approaches and competitive positioning for priority assets.​

Drive cross-functional due diligence for each opportunity, coordinating scientific, clinical, regulatory, and commercial assessments to inform governance decisions.​

Transaction Execution: Partner closely with BD and Regional Ecosystem Leads to advance high-priority opportunities through negotiation and deal close, ensuring seamless handoff and execution​

Represent the TA externally, leading sourcing activities at specialized conferences and cultivating relationships with biotech, academia, and investment communities.​

12+ years in biopharma with significant experience in external innovation, search & evaluation, or business development.​

Advanced degree required (PhD, MD, or equivalent).​

Deep scientific expertise in Immunology, Hematology, or Cardiovascular/Renal therapeutic areas.​

Proven track record of leading due diligence and closing early-stage deals.​

Strong network within biotech, academia, and pharma BD organizations.​